PCB Technologies: Is Miniaturization Moving from Proof Point to Growth Engine
PCB Technologies' miniaturization segment has already crossed from proof of capability to proof of demand: segment sales nearly doubled in 2025, gross profit rose to $3.4 million, and early 2026 brought a $4.8 million order plus a roughly $7 million commercial agreement. But the activity is still small, concentrated, and heavily defense-led, so the real question is no longer whether the technology works, but whether commercialization can broaden.
Starting Point
The main article on PCB Technologies made a simple point: miniaturization was no longer just a nice technology story, but it was still too early to call it a growth engine for the group. This continuation isolates that question because the disclosure thread from early 2026 changes something important. It shifts the discussion from engineering capability to commercialization.
The short answer is yes, but only halfway. Miniaturization has already moved from proof of capability to proof of demand. Segment sales rose from $2.2 million in 2023 to $4.5 million in 2024 and $8.6 million in 2025. Gross profit rose in the same period from $0.45 million to $1.27 million and then to $3.4 million, lifting gross margin from roughly 20.5% to about 39.7%. This is no longer an experimental activity looking for accounting relevance.
But it is still not a full growth engine. In 2025 the segment represented only 4% of consolidated revenue. About 82% of its sales came from the military market, and two military customers generated 74% of segment revenue. In other words, the company has already proven that the product has a market, but it has not yet proven that it has a broad market.
The real change sits in the order ladder. As of December 31, 2025 the segment's backlog stood at $7 million, fully scheduled across the first three quarters of 2026. Only the January and March 2026 disclosures explicitly extended the delivery window into 2027. That is the break line between proof of capability and the start of commercialization.
What Has Already Been Commercially Proven
The segment did not commercialize in one quarter. During 2021 and 2022 the group invested in setting up the activity, built a clean room and advanced microelectronics infrastructure, and officially launched the segment on January 1, 2023. By the end of 2025 it had 12 R&D employees, five approved patents, and about $950 thousand of cumulative Israel Innovation Authority grants across 2023 to 2025. In the investor presentation, management ties the broader push to roughly $43 million of capex over the last five years, about $7.5 million of increased R&D spending, and an expanded engineering layer.
What changed in 2025 is that those investments started to show up in paying-customer economics, not only in capability language. Revenue nearly doubled versus 2024, while gross profit rose about 168%. The margin improvement matters as much as the volume growth. It suggests the first commercial wins were not taken only to establish presence. They are already generating better economics than the segment showed in its launch year.
| Year | Miniaturization segment sales | Gross profit | Gross margin | Share of consolidated revenue |
|---|---|---|---|---|
| 2023 | $2.2 million | $0.45 million | 20.5% | 2% |
| 2024 | $4.5 million | $1.27 million | 27.9% | 3% |
| 2025 | $8.6 million | $3.4 million | 39.7% | 4% |
That chart is the heart of the argument. If miniaturization were still only at the experiment stage, the likely story would be revenue growth without clear economics. Instead, gross profit rose faster than sales. That already says something meaningful about commercialization quality.
There is another clue here. The presentation frames miniaturization as part of a broader one-roof value chain, from PCBs and substrates through IC packaging and into assembly and final product integration. That matters because miniaturization does not necessarily have to stand alone from day one. It can first monetize as another layer sold into existing group relationships. That is a real market-entry advantage, even if it does not solve concentration.
Where Commercialization Is Still Too Narrow
To see why it is still too early to call this a mature growth engine, the mix matters more than the growth rate. In 2025, 82% of miniaturization revenue came from the military market, 16% from civilian markets, and only 2% from medical. The picture was almost identical in 2024, with 83% military. So despite the expansion, the segment still has not shown real commercial diversification across end markets.
And that is only the first layer of concentration. The second layer is sharper: two military customers accounted for 74% of segment revenue. On one hand, that is too concentrated to call the business diversified. On the other hand, revenue from those customers is still below 10% of the group's consolidated revenue. That asymmetry matters. It means concentration is still a problem inside the segment, but not yet something that can destabilize the whole group on its own. Put differently, miniaturization is still too small to bring down the group, but also too small to carry it.
The less obvious limitation is not just the number of customers. It is the width of the commercial system around the technology. In the annual report the company says it already operates local sales teams in Israel and the U.S. and works with agents in Europe. At the same time, the forward-looking slide in the presentation still lists building local operations and a commercial team in the U.S. and EU, alongside diversifying the customer portfolio, as next-year priorities. The reasonable reading is that the technology has advanced faster than the go-to-market system. That is exactly what often happens when proof of capability arrives before market breakout.
The 2026 to 2027 Order Ladder
If there is one place where miniaturization moves from narrative to commercialization, it is here. At year-end 2025 the company showed $7 million of backlog in the miniaturization segment. The quarterly split was very clear: $4 million for Q1 2026, $2 million for Q2, and $1 million for Q3. Nothing was disclosed for Q4 2026 or for 2027. Near the report date, backlog had already risen to $11 million. Then two material disclosures followed: on January 5, 2026 a $4.8 million order with supply from Q2 2026 through Q3 2027, and on March 3, 2026 a commercial agreement with estimated supplies of about $7 million across 2026 and 2027.
That chart intentionally mixes two different types of disclosure: reported backlog on one side, and separately disclosed order or agreement amounts on the other. That is the point. The January and March headlines together create about $11.8 million of nominal disclosed commercial volume, larger than the segment's entire 2025 revenue base. But that should not be read as a clean $11.8 million addition to reported backlog. The March filing is framed as estimated supplies over the delivery period, and the segment's backlog near the report date stood at only $11 million. The correct reading is not that the segment has already fully loaded 2027. It is that the company has, for the first time, disclosed an explicit commercial thread extending visibility beyond what was visible on December 31, 2025.
There is one more clue worth pausing on. In both the January and the March disclosures, the company stated that it already sells additional products to the relevant customer beyond the products covered by the specific order or agreement. That does not prove it is the same customer, and it does not mean every future win will come from existing accounts. But it does suggest that early commercialization in miniaturization is happening, at least in part, as deeper penetration inside industrial and defense relationships the group already has. That fits well with the value proposition in the presentation: miniaturization as another layer plugged into a broader manufacturing stack, not as a detached product sold outside the rest of the group.
So Is This Already a Growth Engine
Not yet, but it is clearly beyond proof of capability. For miniaturization to move from early commercialization to real growth engine status, the company does not need another presentation. It needs three measurable outcomes:
| Checkpoint | What would confirm the thesis | What would delay it |
|---|---|---|
| Revenue conversion in 2026 | Visible revenue recognition from the $4.8 million January order and the roughly $7 million March agreement without material slippage | Delivery delays or a wide gap between win announcements and reported revenue |
| Broader customer base | Lower dependence on the two leading customers and more weight from civilian or medical channels | Continued reliance on the same two military accounts and the same end market |
| Commercial build-out | Clear progress in U.S. and EU commercialization, as management itself outlines in the presentation | Good technology that remains tied to a handful of local defense programs |
That is why miniaturization matters more now than it did in the main article, but is still not clean enough to deserve full growth-engine status. The company has already shown that the technology can leave the lab, win orders, generate gross profit, and extend delivery visibility. What it has not yet shown is breadth, repeatability, and enough commercial scale.
The bottom line is that miniaturization has moved from proof point to commercialization proof. That is an important step, but not the end of the road. A true growth engine begins only when the company can show that this segment is not just profitable, but also repeatable and less dependent on two customers and one military end market.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.